lundi 29 septembre 2014

New data on combination treatments for melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data.

New data on combination treatments for melanoma

Aucun commentaire:

Enregistrer un commentaire